{
  "id": "61f7c60c882a024a10000025",
  "type": "factoid",
  "question": "What is the target of Sotorasib?",
  "ideal_answer": "Sotorasib is a KRASG12C inhibitor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34553354",
    "http://www.ncbi.nlm.nih.gov/pubmed/33547148",
    "http://www.ncbi.nlm.nih.gov/pubmed/34800654",
    "http://www.ncbi.nlm.nih.gov/pubmed/34504076",
    "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
    "http://www.ncbi.nlm.nih.gov/pubmed/33466360",
    "http://www.ncbi.nlm.nih.gov/pubmed/34520956",
    "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
    "http://www.ncbi.nlm.nih.gov/pubmed/34776511",
    "http://www.ncbi.nlm.nih.gov/pubmed/33004338",
    "http://www.ncbi.nlm.nih.gov/pubmed/34607583",
    "http://www.ncbi.nlm.nih.gov/pubmed/34200676",
    "http://www.ncbi.nlm.nih.gov/pubmed/33971321",
    "http://www.ncbi.nlm.nih.gov/pubmed/34158284",
    "http://www.ncbi.nlm.nih.gov/pubmed/34715449",
    "http://www.ncbi.nlm.nih.gov/pubmed/34838325",
    "http://www.ncbi.nlm.nih.gov/pubmed/34607832",
    "http://www.ncbi.nlm.nih.gov/pubmed/34590053",
    "http://www.ncbi.nlm.nih.gov/pubmed/34558391",
    "http://www.ncbi.nlm.nih.gov/pubmed/34675734",
    "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
    "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
  ],
  "snippets": [
    {
      "text": "Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, we show that a selective PI4KA inhibitor augments the antineoplastic activity of the KRASG12C inhibitor\u00a0sotorasib, suggesting a clinical path to exploit this pathway. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, clinical candidates targeting the KRAS G12C protein have recently been developed. MRTX849 and recently approved Sotorasib are covalent binders targeting the mutated cysteine 12, occupying Switch II pocket.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558391",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib with efficacy in kRAS-G12C mutation of NSCLC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553354",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two such inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), were recently evaluated in phase I-III trials for the treatment of non-small cell lung cancer with KRAS-G12C mutations, heralding a new era of precision oncology. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34607583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The findings, along with data on the KRASG12C inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34607832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158284",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced or metastatic NSCLC, following at least one prior systemic therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34800654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these result",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33547148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. In the nonclinical to",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33971321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the clinical validity of Guardant360 CDx as a companion diagnostic for sotorasib for detection of KRAS p.G12C, an important oncogenic NSCLC driver mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34838325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34715449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KR",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mut",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "t efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. L",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33466360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. H",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34200676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "re have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 w",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "gly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. To bett",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "esults of the nonclinical safety program support a high benefit/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "oved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158284",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ered an \"undruggable\" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicite",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33004338",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "er cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on promising results in both preclinical and clinical trials, sotorasib, a novel KRASG12C inhibitor, was given conditional approval by the FDA in May 2021.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34675734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Overall, the results of the nonclinical safety program support a high benefit/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "KRASG12C"
}